Optimal [ 18 F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.123.266384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Geraldine Gebhart und 25 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron Emission Tomography Computed Tomography, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy deescalation in human epidermal growth factor receptor 2 (HER2)-positive, invasive, operable breast cancer with at least 1 breast lesion evaluable by [18F]FDG PET/CT. [18F]FDG PET/CT responders were defined as patients with an SUVmax reduction (ΔSUVmax) of at least 40% in all of their target lesions after 2 cycles of trastuzumab and pertuzumab (HP) (with or without endocrine therapy). In total, 227 of 285 patients (80%) included in the HP arm showed a predefined metabolic response and received a total of 8 cycles of HP (with or without endocrine therapy). Pathologic complete response (pCR), defined as ypT0/isN0, was achieved in 37.9% of the patients. Here, we describe the secondary preplanned analysis of the best cutoff of ΔSUVmax for pCR prediction.
Methods
Receiver-operating-characteristic analysis was applied to look for the most appropriate ΔSUVmax cutoff in HER2-positive early breast cancer patients treated exclusively with neoadjuvant HP (with or without endocrine therapy).
Results
The ΔSUVmax capability of predicting pCR in terms of the area under the receiver-operating-characteristic curve was 72.1% (95% CI, 65.1-79.2%). The optimal ΔSUVmax cutoff was found to be 77.0%, with a 51.2% sensitivity and a 78.7% specificity. With this cutoff, 74 of 285 patients (26%) would be classified as metabolic responders, increasing the pCR rate from 37.9% (cutoff ≥ 40%) to 59.5% (44/74 patients) (P < 0.01). With this optimized cutoff, 44 of 285 patients (15.4%) would avoid chemotherapy in either the neoadjuvant or the adjuvant setting compared with 86 of 285 patients (30.2%) using the original cutoff (P < 0.001).
Conclusion
In the PHERGain trial, an increased SUVmax cutoff (≥77%) after 2 cycles of exclusive HP (with or without endocrine therapy) achieves a pCR in the range of the control arm with chemotherapy plus HP (59.5% vs. 57.7%, respectively), further identifying a subgroup of patients with HER2-addicted tumors. However, the original cutoff (≥40%) maximizes the number of patients who could avoid chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
- Vrije Universiteit Brussel, Brussels, Belgium.
- Hospital Universitario Virgen del Rocío, Seville, Spain.
- Medical Oncology Department, Institut Català D'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
- Hospital Clínico Universitario de Valencia, Valencia, Spain.
- Breast Cancer Group, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Zitieren
APA
Gebhart, G., Keyaerts, M., Guiot, T., Flamen, P., Ruiz-Borrego, M., Stradella, A., Bermejo, B., Escriva-de-Romani, S., Calvo Martínez, L., Ribelles, N., Fernandez-Abad, M., Albacar, C., Colleoni, M., Garrigos, L., Atienza de Frutos, M., Dalenc, F., Prat, A., Marmé, F., Schmid, P., …, & Llombart-Cussac, A. (2024). Optimal [ 18 F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266384
Vancouver
Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, et al. Optimal [ 18 F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.266384
BibTeX
@article{Gebhart2024,
author = {Gebhart, Geraldine and Keyaerts, Marleen and Guiot, Thomas and Flamen, Patrick and Ruiz-Borrego, Manuel and Stradella, Agostina and Bermejo, Begoña and Escriva-de-Romani, Santiago and Calvo Martínez, Lourdes and Ribelles, Nuria and Fernandez-Abad, María and Albacar, Cinta and Colleoni, Marco and Garrigos, Laia and Atienza de Frutos, Manuel and Dalenc, Florence and Prat, Aleix and Marmé, Frederik and Schmid, Peter and Kerrou, Khaldoun and Braga, Sofia and Gener, Petra and Sampayo-Cordero, Miguel and Cortés, Javier and Pérez-García, José Manuel and Llombart-Cussac, Antonio},
title = {Optimal [ 18 F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.123.266384}
}
EUVIMED